Statement: There are several cardiac adverse events recorded in the primary trial, but not a single one in the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 82/217 (37.79%)   Febrile neutropenia 21/217 (9.68%)   Neutropenia 4/217 (1.84%)   Leukopenia 0/217 (0.00%)   Anaemia 1/217 (0.46%)   Thrombocytopenia 0/217 (0.00%)   Atrial fibrillation 0/217 (0.00%)   Arrhythmia 1/217 (0.46%)   Arteriospasm coronary 0/217 (0.00%)   Atrioventricular block first degree 0/217 (0.00%)   Cardiac failure 0/217 (0.00%) Adverse Events 2:   Total: 106/252 (42.06%)   Febrile neutropenia 29/252 (11.51%)   Neutropenia 13/252 (5.16%)   Leukopenia 3/252 (1.19%)   Anaemia 0/252 (0.00%)   Thrombocytopenia 1/252 (0.40%)   Atrial fibrillation 1/252 (0.40%)   Arrhythmia 0/252 (0.00%)   Arteriospasm coronary 1/252 (0.40%)   Atrioventricular block first degree 1/252 (0.40%)   Cardiac failure 1/252 (0.40%)
Secondary_evidence: Adverse Events 1:   Total: 6/40 (15.00%)   Nausea 1/40 (2.50%)   Vomiting 1/40 (2.50%)   Chest pain 1/40 (2.50%)   Hypercalcemia 1/40 (2.50%)   Thromboembolism 2/40 (5.00%)